SOURCE: Implant Sciences

Implant Sciences

August 03, 2011 10:53 ET

Implant Sciences Improves Its Quantum Sniffer Explosives Trace Detectors With New Detection Analysis and Reporting Software

System Produces Usage Metrics, Legal Proof Tools, and Valuable Data for Security Regulators

WILMINGTON, MA--(Marketwire - Aug 3, 2011) - Implant Sciences Corporation (OTCQB: IMSC) (PINKSHEETS: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced it is enhancing its Quantum Sniffer™ QS-H150 and QS-B220 explosives trace detection devices with an advanced performance logging and reporting system. This new software package, offered as an accessory, will be available to the Company's current installed base of over 1,300 QS-H150 units as well as being offered in future QS-B220 and QS-H150 sales.

Running on a personal computer, the new software tool allows users to collect data from multiple Quantum Sniffers into a single data repository where it can be queried and organized to produce detailed reports. Information captured includes the time of scan, the system operator, substances detected (if any), and detailed analysis information for each positive detection.

The reports created by this system are of critical importance to government regulators who require metrics on detection equipment used for air cargo screening and at border and security checkpoints. The ability to precisely track usage also assists security administrators in optimizing system deployments as well as allowing the implementation of pay-per-scan compensation for security services. A detailed scan report is also provided that may be used as evidence submitted to court if and when scans result in legal proceedings.

"These new reporting capabilities significantly improve the value proposition and competitiveness of our QS-H150 and QS-B220 explosives trace detection equipment. Current and prospective customers have responded very positively to this product upgrade. We believe the logging and reporting capabilities will quickly lead to additional sales from both current and future customers," stated Implant Sciences CEO Glenn D. Bolduc.

About the Quantum Sniffer QS-H150

The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer QS-B220

The QS-B220 Quantum Sniffer, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact